GenomeNext Launches Innovative Olympus Platform to Integrate Genetic Testing, Delivering Fully Automated Solution to Drive Personalized Medicine Programs
September 27, 2016
Columbus, OH – GenomeNext, LLC, a leader in genomic data management and integrated analysis, announced today the launch of Olympus; a powerful, innovative platform designed to simplify and automate ‘Omics-based analysis and interpretation into a single, consolidated solution. The Olympus Platform eliminates the need to invest in, architect and manage multiple, fragmented solutions required to deliver quality, actionable results.
The Olympus platform delivers the market the most cost-effective, true end-to-end, fully integrated ‘Omic analysis solution, requiring no investment in bioinformatics,, workflow engineering, hardware or infrastructure. A unified, automated workflow and data management solution connecting directly with NGS (next generation sequencing) instrumentation to provide analysis, interpretation and storage, including big data genetic association and multivariate analytic capabilities. Unique to Olympus is the capability to interface with EHR (electronic health records) and LIMS (laboratory information management systems) delivering a continuous workflow to scale and manage personalized medicine initiatives.
James Hirmas, GenomeNext CEO stated “Olympus delivers a dynamic, holistic NGS analytical platform designed to eliminate the need for bioinformatic intervention enabling valuable resources to focus efforts on scientific discovery and clinical decision support rather than engineering and managing modular infrastructure components and workflow.”
Olympus’ dynamic configuration enables rapid, scalable deployment for smaller discovery operations, core sequencing and clinical diagnostic laboratories, government driven initiatives and large integrated health systems to equally capitalize on efficiencies. These include dramatic savings on operational costs including compute analysis and storage simultaneously eliminating costly bottlenecks and resource requirements. Furthermore, Olympus offers a zero-risk solution devoid of upfront financial investments facilitating the opportunity for institutions to efficiently on-board capability rapidly and securely.
A key feature of Olympus is to provide unprecedented data quality at speed delivering integrated, actionable results from instrument to interpretation in just hours significantly contributing to an organization’s ability to accelerate discovery and impact patient care. Olympus provides the only reproducible DNA (germline and somatic) analysis solution critical for effective discovery and diagnostics as well as RNA analytics and the ability to seamlessly integrate other ‘Omics based tool sets on a secure, regulatory compliant network. Olympus also integrates an in-platform genome visualization tool completely eliminating the need to download and manually manage large data files for interpretation.
Complementing Olympus is a novel new Discovery Analytics platform providing the ability to perform complex discovery and genetic association studies in a matter of minutes combining the entire set of clinical assessments and sample specific conditions (genomic, phenotypic, biospecimen, demographic, pharmacological, etc.) of an individual patient or cohort of patients to identify disease specific markers and prognostic and diagnostic signatures at a peta-byte scale.
About GenomeNext - GenomeNext is a genomic informatics company dedicated to accelerating the promise and capability of predictive medicine and scientific discovery. We commercialize genomic analysis tools and integrated systems for the evaluation of genetic variation and function. Our advanced informatics and data management solutions are designed to simplify, expedite and enhance genetic analysis workflows. Our solutions provide the market with genomic data and analysis at an unprecedented combination of performance, quality, cost and scale without requiring the investment in high-performance computing resources and specialized personnel. For more information, visit www.genomenext.com.